An interventional study of Dignity Therapy in End of Life, sponsored by Memorial Sloan Kettering Cancer Center. Active, not recruiting at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-08.
Sponsored by Memorial Sloan Kettering Cancer Center · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 118 studies in Death with a site in United States — 13 open to participants now, 27 under way, 1 of them phase 3. Death · United States.
Among the 118 studies in Death with a site in United States, this one is the 71st largest by enrollment of the 79 interventional ones that give a count, is one of 9 that started in 2024, is one of 68 with no phase, reaches primary completion later than 11 of the 26 other live ones, and was the 103rd registered.
457 studies on the registry are indexed under Death; 85 are open to participants now.
Browse Death studies →13 of the 118 studies in Death with a site in United States are open now. Recruiting first, the newest first:
University of Michigan · Sites in United States
Ages 18+
University of Illinois at Chicago · Sites in United States
Ages 18–80
Massachusetts General Hospital · Sites in United States
Yaolin Pei · Sites in United States
Ages 21–99
Fred Hutchinson Cancer Center · Sites in United States
Ages 18+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 58 Death studies recruiting now, 43 (74%) set no upper age limit and 8 (14%) stop at 75 or younger; 11 take children under 18; 14 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
118 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 4 · Phase 3 6 · Phase 4 1
First in 1980; this study’s year is marked. 9 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 15 is below the median of 160 across 211 interventional studies indexed under Death.
Median enrollment 154 across the 79 interventional studies, 272 across the 39 observational. Of the 78 that completed or were terminated, 17 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 118 have an industry lead sponsor. The 10 most frequent:
Memorial Sloan Kettering Cancer Center is the lead sponsor of 1,964 studies on the registry; 325 are open to participants now.
Of its 135 completed or terminated interventional studies of FDA-regulated products, 71 (53%) have results posted.
Memorial Sloan Kettering Cancer Center has 1 study filed under Death — fewer than ten, so there is no comparison to draw.
7 of the studies in Death with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06293456Memorial Sloan Kettering Cancer CenterStudy of Poetic Dignity Therapy for Sexual and Gender Minority Patients With Cancer | 2027-01 |
| NCT04261088National Institutes of Health Clinical Center (CC)Assisted Suicide in Switzerland | 2027-01-31 |
| NCT05446272University of PennsylvaniaThe Diaphragmatic Initiated Ventilatory Assist (DIVA) Trial | 2027-03-31 |
| NCT04515810Fred Hutchinson Cancer CenterMobile Health Application (PACT) to Improve Engagement in Advance Care Planning | 2027-05-31 |
| NCT07370311Yaolin PeiA Culturally Adapted Decision Aid Intervention to Support Chinese American Dementia Caregivers in Feeding-Related Decisions | 2027-07-31 |
Add all 7 to your calendar (.ics) → With an account.
Among the 118 studies in Death with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to find out if dignity therapy is practical and works well for sexual and gender minority (SGM) patients in MSK. SGM includes, but is not limited to, people who identify as lesbian, gay, bisexual, transgender, and/or queer/questioning (LGBTQ+). Dignity therapy is a type of psychotherapy where the clinician asks the patient questions to allow the patient to express their individual life story and ultimately be able to create a legacy document of their experiences that can be shared with their loved ones.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
English-speaking as per the English language assessment items below and wil ing to receive the intervention in English.
o What is the participant's preferred language?
(Specify Lang)___________________________
Exclusion Criteria:
The DT intervention is a 45-75-minute virtual interview, which is recorded and transcribed within 1-2 weeks of the interview.
Other: Dignity Therapy
A trained research staff member will conduct the DT interview virtually. The interview will occur or by phone only if the participant lacks access to technology for videoconferencing. The interviewer asks a series of open-ended questions that encourages patients to talk about their lives and what matters most to them.
the number of patients who complete the intervention
This requires meeting both of the following criteria: i) collection of the DT Interview for 30 patients; and ii) delivery of the poem to at least 22 (\>75%) participants.
Time frame: 1 year
Plan to share: Yes — Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.
Started Jan 2024 (actual). Primary completion is estimated for Jan 2027, 36 months after the start.
Of 107 non-industry interventional studies with no phase under Death, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 48. This study's planned 36 months is above that.
Counting every sponsor, half of 111 studies reached it within 23 months; a quarter within 13 and three quarters within 48.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Memorial Sloan Kettering Cancer Center →